Disitamab vedotin targets HER2 on tumor cells, is internalized, and releases MMAE, which binds the beta‑tubulin vinca domain to block microtubule polymerization, causing G2/M arrest and apoptosis. Beta‑tubulin expression alone does not confer selective killing.